ARV-trial.com CORAL-I study cohorts 3 to 6: OBV/PTV/r + DSV + RBV in transplant recipients and genotype 1 or 4 Design W12 W24 No randomisation Open-label ≥ 18 years HCV infection, genotype 1 or 4 Naïve or (PEG-) IFN ± RBV experienced HCV RNA > 1000 IU/mL Liver (LT) or renal transplant (RT) recipients Compensated cirrhosis or no cirrhosis Immunosuppressive regimen with tacrolimus or cyclosporine ; corticosteroids ≤ 10 mg/day permitted No HBV or HIV co-infection GT1a, N = 4 OBV/PTV/r + DSV + RBV Cohort 3 Genotype 1, LT, cirrhosis GT1b, N = 2 OBV/PTV/r + DSV + RBV GT1a, N = 22 Cohort 4 Genotype 1, LT, no cirrhosis OBV/PTV/r + DSV + RBV GT1b, N = 12 OBV/PTV/r + DSV GT1a, N = 9 OBV/PTV/r + DSV + RBV Cohort 5 Genotype 1, RT, no cirrhosis GT1b, N = 3 OBV/PTV/r + DSV No cirrhosis, N = 4 Cohort 6 Genotype 4, LT, OBV/PTV/r + RBV Cirrhosis, N = 1 OBV/PTV/r + RBV Treatment regimens Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r): 25/150/100 mg QD = 2 tablets Dasabuvir (DSV): 250 mg BID ; RBV: 1000 or 12000 mg/day divided twice daily Objective SVR12 (HCV RNA < 25 IU/mL), with 95% CI, by ITT, descriptive analysis CORAL-I , cohorts 3-6 Agarwal K, EASL 2017, Abs. FRI-267 1

Baseline characteristics ARV-trial.com CORAL-I study cohorts 3 to 6: OBV/PTV/r + DSV + RBV in transplant recipients and genotype 1 or 4 Baseline characteristics Genotype 1 Genotype 4 Cohort 3 LT, cirrhosis N = 6 Cohort 4 LT, no cirrhosis N = 34 Cohort 5 RT, no cirrhosis N = 12 Cohort 6 LT N = 3 Female, % 33 12 25 White, % 100 97 58 Genotype 1a / 1b, % 67 / 33 62 / 35 75 / 25 - HCV RNA > 800 000 IU/mL, % 83 85 IFN/PEG-IFN experienced, % 50 71 17 Cyclosporine / Tacrolimus, % 17 / 83 12 / 88 8 / 92 0 / 100 F0-F1/ F2 / ≥ F3, % 0 / 0 / 100 68 / 19 / 13 75 / 8 / 17 100 / 0 / 0 CORAL-I , cohorts 3-6 Agarwal K, EASL 2017, Abs. FRI-267 2

SVR12 by subgroup, ITT population ARV-trial.com CORAL-I study cohorts 3 to 6: OBV/PTV/r + DSV + RBV in transplant recipients and genotype 1 or 4 SVR12 by subgroup, ITT population Genotype (N) Cirrhosis Regimen, duration SVR12 Cohort 3 Liver transplant Genotype 1a (N = 4) Yes OBV/PTV/r + DSV + RBV 24 weeks 100% Genotype 1b (N = 2) OBV/PTV/r + DSV ± RBV 12 weeks Cohort 4 Genotype 1a (N = 22) No 95% * Genotype 1b (N = 12) OBV/PTV/r + DSV Cohort 5 Renal transplant Genotype 1a (N = 9) 67% ** Genotype 1b (N = 3) Cohort 6 Genotype 4 (N = 2) OBV/PTV/r + RBV Genotype 4 (N = 1) * 1 virologic failure ; ** 3 premature discontinuations CORAL-I , cohorts 3-6 Agarwal K, EASL 2017, Abs. FRI-267 3

ARV-trial.com CORAL-I study cohorts 3 to 6: OBV/PTV/r + DSV + RBV in transplant recipients and genotype 1 or 4 Adverse events, % Genotype 1 Genotype 4 Cohort 3 LT, cirrhosis N = 6 Cohort 4 LT, no cirrhosis N = 34 Cohort 5 RT, no cirrhosis N = 12 Cohort 6 LT N = 3 Any adverse event 100 92 AE leading to discontinuation * 3 17 Serious AE 9 33 Death ** 8 AE in ≥ 10% of patients Fatigue Pruritus Headache Nausea Diarrhea Insomnia 67 100 33 50 17 33 35 24 27 12 15 9 17 8 17 17 8 8 0 33 0 0 0 0 * Nausea and vomiting leading to withdrawal of consent (N = 1), atypical pneumonia with acute renal injury followed by acute respiratory failure (N = 1), and tacrolimus overdose (N = 1) ** 1 patient (tacrolimus overdose) CORAL-I , cohorts 3-6 Agarwal K, EASL 2017, Abs. FRI-267 4

Laboratory abnormalities, % ARV-trial.com CORAL-I study cohorts 3 to 6: OBV/PTV/r + DSV + RBV in transplant recipients and genotype 1 or 4 Laboratory abnormalities, % Genotype 1 Genotype 4 Cohort 3 LT, cirrhosis N = 6 Cohort 4 LT, no cirrhosis N = 34 Cohort 5 RT, no cirrhosis N = 12 Cohort 6 LT N = 3 Hemoglobin 6.5 - 8 g/dL < 6.5 g/dL 10 6 8 Total bilirubin > 3 - 10 x ULN > 10 x ULN 12 ALT > 5-20 x ULN > 20 x ULN AST CORAL-I , cohorts 3-6 Agarwal K, EASL 2017, Abs. FRI-267 5

CORAL-I study cohorts 3 to 6: OBV/PTV/r + DSV + RBV in transplant recipients and genotype 1 or 4 Summary In liver transplant recipients with or without cirrhosis and infected with HCV genotype 1 or 4, treatment with OBV/PTV/r + DSV + RBV was associated with high SVR12 rates and good tolerability In renal transplant recipients, SVR12 was achieved in 9/12 patients, with 3 premature discontinuations due to adverse events, including 1 fatality Need for tacrolimus dose reduction and therapeutic drug monitoring of tacrolimus levels to manage the interaction with ritonavir Patients with genotype 1b achieved SVR12 of 100% with RBV-free regimens CORAL-I , cohorts 3-6 Agarwal K, EASL 2017, Abs. FRI-267